Cavitation Technologies 2026: Revenue $0 Net income ($208K), EPS $0— 10-Q Summary
Cavitation Technologies reported 2026 Q2 revenue of $0, down from $3K YoY, with net loss narrowing to $208K. Prior-year revenue was from a Nano Reactor rental. A 2024 patent transfer to Desmet may reduce future sales. The company's water-treatment system is being tested, with sales of Barmuze and Hydro-Plasma expected in 2027.
How this was made
The 30-second read
Why it matters
The earnings release confirms continued revenue challenges and modest loss improvement, with future upside tied to pending product trials and partner manufacturing.
Market read
Minimal market relevance due to the company's tiny size and lack of revenue; only niche micro‑cap traders may react.
What to watch
Potential upside from the Desmet partnership and upcoming hydro‑plasma trials, which are not reflected in the current numbers.
Background
Cavitation Technologies (CVAT) released its Q4 2026 10‑Q, showing zero revenue and a narrowed net loss. The filing mentions a patent assignment to Desmet and ongoing trials for water‑treatment and hydro‑plasma systems.
Ticker impact
Cavitation Technologies filed its 10‑Q reporting Q4 2026 revenue of $0 and a net loss of $208K, a fresh quarterly earnings disclosure.
likely limited pressure as investors price in continued losses and low revenue outlook
The company’s tiny scale and zero revenue suggest minimal market reaction; any price move will be driven by liquidity rather than fundamentals.
Market effects
No material impact on the broader water‑treatment or plasma‑tech sectors.
Limited to niche investors in the micro‑cap space.
None
Counterpoint
If the company secures the anticipated contracts in 2027, the current loss could be a buying opportunity.
Key entities
- companyCavitation Technologies
Micro‑cap firm reporting Q4 2026 results.
- companyDesmet
Recipient of a patent assignment; expected to manufacture reactors.
